SITC's Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.
As “living drugs,” the adverse events associated with immune effector cell (IEC) therapy differ markedly from those seen with other anti-cancer regimens. Although IEC-related adverse events are generally manageable with proper supportive care, the toxicities that do occur may have more rapid onset and can progress to life-threatening complications. Therefore, timely recognition and appropriate management of these toxicities are vital for safe use of IEC.
To provide expert guidance to practicing clinicians using IEC therapies and ensure the best outcomes for patients, the SITC established the Immune Effector Cell-related Adverse Expert Panel that included expert perspectives from physicians, nurses, patients, and patient advocates. The Expert Panel is currently developing recommendations for addressing some of the most commonly reported toxicities during treatment with FDA-approved CAR T cell therapies as well as other emerging IEC therapies, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and persistent cytopenias and resultant infections, among other key considerations for oncologists treating their patients with these agents. A companion guideline on the management of immune checkpoint inhibitor-related adverse events published on June 25, 2021 in the Journal for ImmunoTherapy of Cancer (JITC).
Published December 16, 2020 in the Journal for ImmunoTherapy of Cancer (JITC) as "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events"SITC is a proponent for collaboration and harmonization of efforts between like-minded organizations whenever possible. SITC wishes to thank the American Society of Hematology (ASH), the American Society for Transplantation and Cellular Therapy (ASTCT) and the Foundation for the Accreditation of Cellular Therapy (FACT) at the University of Nebraska Medical Center for providing representatives to serve on SITC’s Immune Effector Cell-related Adverse Events Expert Panel to aid in the development of this clinical practice guideline.
SITC is pleased to offer free webinars featuring Expert Panel members from SITC's Immune Effector Cell-related Adverse Events Guideline. These educational offerings are designed for healthcare providers who treat cancer patients including oncologists, physicians, disease specialists, registered nurses, nurse practitioners, pharmacists and physician assistants. The live webinars include a dedicated question-and-answer session providing the opportunity for attendees to converse with the faculty and ask questions about the guideline recommendations.
In this introductory webinar, Expert Panel members provide attendees with an overview of the published guideline and highlight selected recommendations that are applicable to some of the most common scenarios clinicians may encounter while treating their patients with immunotherapy. After attending this webinar, learners will be better able to implement immunotherapy treatments effectively and in accordance with the recommendations in the SITC CPG.
This advanced webinar is designed so that attendees will know how to appraise and classify organ-specific considerations for immunotherapy agents and toxicities, identify and manage clinically significant uncommon toxicities, and determine optimal sequencing of immunotherapies in relapsed and/or refractory disease.
Faculty engage attendees through a combination of case presentations with a “virtual tumor board” discussion and Q&A with diverse sub-specialty experts based on the needs of each particular case. This high-level webinar is designed so attendees will be able to execute the use of immunotherapy with increased confidence, plan management strategies for difficult cases, and identify and discuss areas of controversy in the immunotherapy field.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com